{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1533, 
        1539
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1540, 
        1549
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        734, 
        757
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1045, 
        1068
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3301, 
        3321
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4378, 
        4398
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1397, 
        1424
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1668, 
        1695
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1784, 
        1811
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1480, 
        1485
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        460, 
        489
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1524, 
        1532
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1486, 
        1492
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1494, 
        1498
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 11^9311^MOH|PIMS|CCO|20160601115321|A85A9D8A1D8B480AFF287A54FEE0F15AC36DC6DE|ORU^R01|99999999999999999999|P|2.5|||||\nPID|1||^^^^MRN^HOSPITAL 11&9999&MOH~9999999999&TD&ON^^^^JHN||XXXXXX^XXXXXX^XXXXXXXX||99999999|F|||999 XXXXXXXXX XXX.^^XXXXXXX^XX^X9X9X9^999|||||||||||||||||||N|\nOBR|1||BZ00605443|11529-5^Surgical Pathology Study Report^LN^BX^Biopsy^L|||20160516|||52514^XXXX^XXXXX^XXXX^^XX.||||||||||||20160601|||C||||||||\n\n\n\n\n\n\n\nPath report.gross description\n\nSpecimen consists of 3 tan tissue cores measuringnE\\15, 17 and 18 mm and 2 fragments measuring innE\\total 2 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\\At the time of embedding MLT found 3 cores and 2nE\\fragments.nE\\\n\n\nPath report.relevant Hx\n\nSpecimen (site and type):  Right Breast,nE\\8 oclocknE\nE\\Ischemic Time: Not ProvidednE\nE\\Fixation Used: Not ProvidednE\nE\\Fixation Duration: Not ProvidednE\\\n50 year old female with 2-4/52 0/0 painful massnE\\at 8:00 positionnE\\Right breast - ultrasound shows BIRADS 4 - 2.5 cmnE\\massnE\\\n\n\nPath report.relevant Hx\n\nKMH - 2075 Hadwen RoadnE\\Mississauga, Ontario L5K 2L3nE\\Phone: 1-905-855-1860 / Fax: 1-905-855-1863nE\nE\nE\\Referring Specimen ID #: N/AnE\\*Block #: N/AnE\\Specimen Type: Core BiopsynE\\Specimen Site: Right BreastnE\\Diagnosis:  Invasive ductal carcinomanE\\*If more than one block was submitted please seenE\\additional report.nE\\\n\n\nPath report.final diagnosis\n\nMicroscopic findings incorporated in Diagnosis.nE\nE\nE\\RIGHT BREAST, 8:00 OCLOCK, CORE BIOPSY:nE\\- INVASIVE DUCTAL CARCINOMA, PLEASE SEEnE\\NOTE.nE\nE\\NOTE: Immunostain p63 confirms invasion. BreastnE\\biomarker synoptic report is enclosed.nE\\\n\n\nPath report.final diagnosis\n\nER:PositivenE\\PgR: PositivenE\\HER2 IHC: Equivocal (2+)nE\\HER2 FISH: Non-amplifiednE\\\n\n\nPath report.final diagnosis\n\nER Result: PositivenE\\Percentage of invasive tumour cells with nuclearnE\\positivity: 90-100nE\\Average intensity of staining: StrongnE\\External Control staining: AdequatenE\\Internal Control staining: Present and ERnE\\PositivenE\nE\\ER antibody used: EP1 Antibody, Dako, PT LinknE\\High pH, EnVision FLEX Detection, DABnE\nE\\(PgR)nE\\PgR Result: PositivenE\\Percentage of invasive tumour cells with nuclearnE\\positivity: 90-100nE\\Average intensity of staining: StrongnE\\External Control staining: AdequatenE\\Internal Control staining: Present and PgRnE\\PositivenE\nE\\PgR antibody used: PgR 636 Antibody, Dako, PTnE\\Link High pH, EnVision FLEX Detection, DABnE\nE\\HercepTestnE\\HER2/neu Interpretation: Equivocal (2+)nE\\Percentage of invasive tumour cells with uniformnE\\intense complete membrane staining: 0nE\\External QC: AdequatenE\nE\\HER2 antibody used: Health Canada ApprovednE\\HercepTest Kit, DakonE\nE\\IQFISHnE\\QC: ?Adequate?nE\\Heterogenous Signals: ?Absent?nE\nE\\Number of cells counted: 30nE\\Average number of HER2/neu signals per nucleusnE\\counted: 2.3nE\\Average number of CEP17 signals per nucleusnE\\counted: 1.7nE\\The ratio of HER2neu/CEP17: 1.4nE\nE\\HER2/neu FISH Interpretation: Non-amplifiednE\\HER2/neu FISH read and reported by:nE\\?MLT: M. McClanaghan?nE\\?Pathologist: Dr. D. Pilavdzic?nE\nE\\Dual Probe(s) Used: HER2/CEN-17 Probe MixnE\\Method: Dako, HER2 IQFISH pharmDx Kit, CodenE\\K5731, FDA and Health Canada approved.nE\nE\\Please see Laboratory Reference Ranges onnE\\Following PagenE\\\n\n\nPath report.comments\n\nThis report is available in ClinicalConnectnE\\(OLIS) and Dynacares eResults.nE\nE\\Cold ischemic time: not specifiednE\nE\\Total fixation time: not specifiednE\nE\\Cold ischemia and fixation times meet thenE\\requirements specified in the latest versionnE\\(2013) of the ASCO/CAP guidelines for reportingnE\\results of the biomarker testing of specimensnE\\from patients with carcinoma of the breast.nE\nE\\X NonE\nE\\All breast biomarkers are validated with tissuenE\\fixed in 10% NBF for 6 to 72 hours, according tonE\\2013 ASCO/CAP guidelines. The methods are notnE\\validated for shorter or longer fixation in NBF,nE\\other fixatives, cold ischemic time more than 60nE\\minutes, treatment of tissue with microwaves,nE\\decalcification or the use of mercurochrome. IfnE\\the handling of the sample falls outside of thenE\\acceptable parameters, the results will benE\\considered non-validated.nE\\Dynacare Next Molecular and Cellular PathologynE\\Laboratory participates in the HER2/neunE\\Provincial Quality Assurance Program as well asnE\\EQA programs with cIQc and IQMH.nE\\\n\n\nPath report.comments\n\nReporting Results on ER and PgR TestingnE\nE\\Result:  PositivenE\\Criteria: Immunoreactive tumor cells presentnE\\(>/=1%)nE\\Comments - The percentage of immunoreactivenE\\cells may be determined by visualnE\\estimation or quantification. Quantification cannE\\be provided by reporting the percentage ofnE\\positive cells or by a scoring system, such asnE\\the Alfred score or H score.nE\nE\\Result:  NegativenE\\Criteria: <1% immunoreactive tumor cells presentnE\nE\\Reporting Results of HER2 Testing bynE\\Immunohistochemistry (IHC)nE\nE\\Result:   Negative (Score 0)nE\\Criteria:  No staining observed or incomplete,nE\\faint/barely perceptible membrane staining innE\\</=10% of invasive tumor cellsnE\nE\\Result:  Negative (Score 1+)nE\\Criteria: Incomplete, faint/barely perceptiblenE\\membrane staining in >10% of invasive tumornE\\cells*nE\nE\\Result:  Equivocal (Score 2+)**nE\\Criteria: Incomplete and/or weak to moderatenE\\circumferential membrane staining in >10% ofnE\\invasive tumor cells or Complete, Intense,nE\\circumferential membrane staining in </=10% ofnE\\invasive tumor cells*nE\nE\\Result:  Positive (Score 3+)nE\\Criteria: Complete, Intense, circumferentialnE\\membrane staining in >10% of invasive tumornE\\cells*nE\nE\\*Readily appreciated using low-power objectivenE\\and observed within a homogenous and contiguousnE\\population of invasive tumor cells.nE\\**Must order reflex in situ hybridization testnE\\(same specimen) or new test (new specimen ifnE\\available, using immunohistochemistry or in situnE\\hybridization).nE\nE\\Reporting Results of HER2 Testing by in SitunE\\Hybridization (dual-probe assay)nE\nE\\Result:   Negative (not amplified)nE\\Criteria:  HER2/CEP17 ratio <2.0 AND averagenE\\HER2 copy number <4.0 signals/cellnE\nE\\Result:   Equivocal*nE\\Criteria:  HER2/CEP17 ratio <2.0 AND averagenE\\HER2 copy number >/=4.0 but < 6.0 signals/cell*nE\nE\\Result:   Positive (amplified)nE\\Criteria:  HER2/CEP17 ratio >2.0** (regardlessnE\\of average HER2 copy number) ornE\\Average HER2 copy number >/=6.0 signals/cell**nE\\(regardless of ratio)nE\nE\\*Must order a reflex test (same specimen usingnE\\immunohistochemistry),nE\\Test with alternative in situ hybridizationnE\\chromosome 17 probe, or order a new test (newnE\\specimen if available, using immunohistochemistrynE\\of in situ hybridization).nE\\**Observed in a homogenous and contiguousnE\\population of >/= 10% of invasive tumor cells.\n\n\n"
}